Wei Guo

Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer.

S. Ellard, V. Moreno, R. Kristeleit, 2018, Annals of Oncology.